A 72-year-old woman with hypertension and stage 4 CKD (eGFR 22 mL/min/1.73m²) is admitted with a 3-day history of nausea, fatigue, and constipation. She has been on amlodipine, enalapril, and atorvastatin for 5 years. Her grandson recently gave her NSAIDs for back pain, which she took for 2 days. Laboratory findings: K⁺ 6.8 mEq/L, Na⁺ 138 mEq/L, Cl⁻ 104 mEq/L, HCO₃⁻ 18 mEq/L, creatinine 3.2 mg/dL, pH 7.28, PaCO₂ 32 mmHg. ECG shows peaked T waves but no PR prolongation or QRS widening. Which of the following is the MOST important step in preventing recurrence of hyperkalemia in this patient?

Explanation

## Clinical Context This patient has **moderate-to-severe hyperkalemia** (K⁺ = 6.8 mEq/L) in the setting of: - Advanced CKD (eGFR 22) with reduced urinary K⁺ excretion - ACE inhibitor use (enalapril) → ↓ aldosterone → ↓ distal K⁺ secretion - **Acute kidney injury superimposed on CKD** (creatinine rose acutely from baseline, likely due to NSAID-induced prerenal azotemia) - Metabolic acidosis (pH 7.28, HCO₃⁻ 18) → shifts K⁺ OUT of cells, worsening hyperkalemia - **NSAID exposure** — the precipitant The question asks about **prevention of recurrence**, not acute management. This shifts focus from immediate stabilization (calcium, insulin) to **long-term risk reduction**. ## Why Option 2 (Dietary K⁺ Restriction + NSAID Avoidance) Is Correct **Key Point:** In CKD with hyperkalemia, the two most modifiable risk factors are **dietary potassium intake** and **NSAID exposure**. Addressing these prevents recurrence. ### Mechanism of Prevention 1. **Dietary K⁺ restriction (<2 g/day)**: - In CKD, the kidney cannot excrete excess dietary K⁺. - Reducing intake directly reduces the serum K⁺ burden. - This is **sustainable, non-pharmacologic, and evidence-based**. 2. **NSAID avoidance**: - NSAIDs cause **prerenal azotemia** by reducing glomerular filtration pressure (via COX inhibition → ↓ PGE₂ → vasoconstriction). - They also **inhibit renin release**, reducing aldosterone-mediated K⁺ excretion. - NSAIDs are a **major, modifiable trigger** for hyperkalemia in CKD. - Patient education on this is critical — many patients do not realize OTC NSAIDs are dangerous. **High-Yield:** In CKD hyperkalemia, ask: "What can the patient STOP or REDUCE?" The answer is usually dietary K⁺ and NSAIDs, not adding new drugs. ## Why Each Distractor Is Suboptimal ### Option 0: Discontinue Enalapril, Start Amlodipine Monotherapy **Clinical Pearl:** While discontinuing enalapril would lower K⁺ (by removing the aldosterone-suppressing effect), this is **not the most important step** for several reasons: 1. **Enalapril is cardioprotective**: In CKD and hypertension, ACE inhibitors slow progression of renal disease and reduce cardiovascular mortality. Stopping it without strong indication is harmful. 2. **The real culprit is the NSAID**: The acute rise in K⁺ and creatinine is due to NSAID-induced prerenal AKI superimposed on CKD, not enalapril alone. 3. **Amlodipine monotherapy is inadequate**: Blood pressure control will be suboptimal, accelerating CKD progression. 4. **Better approach**: Continue enalapril, but **address the NSAID exposure and dietary K⁺**. **Warning:** Do not reflexively stop RAAS inhibitors in hyperkalemia without considering the clinical context. Often, the precipitant (NSAID, infection, dehydration, medication non-compliance) is the real problem. ### Option 1: Initiate Hemodialysis Three Times Weekly **Why this is premature:** 1. **eGFR 22 does not automatically mandate dialysis**: Dialysis is indicated when eGFR <15 (stage 5) AND the patient is symptomatic or cannot manage conservatively. 2. **This patient's hyperkalemia is acute and precipitated**: Once NSAIDs are stopped, dietary K⁺ is restricted, and acidosis is corrected, K⁺ may normalize without dialysis. 3. **Dialysis is invasive**: It carries risks (vascular access complications, infection, cardiovascular instability) and should not be started for a single episode of hyperkalemia in stage 4 CKD. 4. **Cost and quality of life**: Dialysis is a major commitment; it is not the answer to preventable hyperkalemia. **Clinical Pearl:** Dialysis is the **definitive** therapy for end-stage renal disease, not a preventive measure for hyperkalemia in stage 4 CKD. ### Option 3: Start Fludrocortisone 0.1 mg Daily **Why this is inappropriate:** 1. **Fludrocortisone is a mineralocorticoid**: It increases Na⁺ reabsorption and K⁺ excretion in the distal tubule. 2. **Mechanism**: Fludrocortisone activates the mineralocorticoid receptor, mimicking aldosterone. 3. **BUT — this patient has hypertension**: Fludrocortisone causes **sodium retention and volume expansion**, worsening hypertension and potentially precipitating heart failure or pulmonary edema. 4. **Limited role**: Fludrocortisone is reserved for **hyperkalemia in the context of hypoaldosteronism** (e.g., type 4 RTA, adrenal insufficiency), not for CKD-related hyperkalemia in a hypertensive patient. 5. **Contraindicated here**: The patient's baseline blood pressure is likely elevated (on amlodipine + enalapril); adding a sodium-retaining agent is dangerous. **Warning:** Fludrocortisone is not a standard preventive therapy for CKD hyperkalemia and carries significant cardiovascular risk in this population. ## Summary Table: Hyperkalemia Management Strategies in CKD | Strategy | Mechanism | Role in Prevention | Feasibility | Risks | |----------|-----------|-------------------|-------------|-------| | **Dietary K⁺ restriction** | ↓ K⁺ intake → ↓ serum K⁺ | **Primary** | High | None if counseled properly | | **NSAID avoidance** | Prevents prerenal AKI, preserves aldosterone | **Primary** | High | Patient education needed | | **ACE inhibitor continuation** | Renal protection; mild K⁺ retention acceptable | Supportive | High | Only if other triggers controlled | | **Diuretics** (loop or thiazide) | ↑ K⁺ excretion | Secondary (if urine output adequate) | Moderate | Hypotension, worsening renal function | | **Cation exchange resin** | Binds K⁺ in GI tract | Chronic management | Moderate | Constipation, hypernatremia | | **Fludrocortisone** | Mineralocorticoid effect | Niche (hypoaldosteronism only) | Low in CKD | HTN, volume overload, contraindicated | | **Dialysis** | Removes K⁺ directly | Definitive (stage 5 CKD) | Low (invasive) | Vascular access, infection, hemodynamic stress | ## Mnemonic: **PREVENT Hyperkalemia in CKD** - **P**otassium restriction (dietary) - **R**ecognize NSAIDs as a trigger - **E**valuate and treat acidosis - **V**ascular disease prevention (continue ACE inhibitor) - **E**ducate patient on triggers - **N**ephrology referral if recurrent - **T**reat underlying CKD progression [cite:Harrison 21e Ch 280; Kidney Disease: Improving Global Outcomes (KDIGO) 2021 CKD Guidelines]